BACE1 and Alzheimer disease: BACE1 is validated as an early AD biomarker (Hampel et al., 2020), while a multiplicity of environmental and genetic risk factors for AD are shown to converge on increased BACE1 level/activity in animal models and clinical settings (Ohno, 2025).